OnKure Therapeutics (NASDAQ:OKUR) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

OnKure Therapeutics (NASDAQ:OKUR) posted its earnings results on Thursday. The company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.16, FiscalAI reports.

OnKure Therapeutics Price Performance

Shares of NASDAQ OKUR traded down $0.01 during mid-day trading on Thursday, hitting $3.52. 97,227 shares of the company’s stock traded hands, compared to its average volume of 113,490. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $5.28. The company’s 50-day moving average is $2.81 and its two-hundred day moving average is $2.86. The company has a market capitalization of $47.69 million, a P/E ratio of -0.73 and a beta of 0.45.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OnKure Therapeutics currently has an average rating of “Hold” and an average price target of $34.00.

Institutional Investors Weigh In On OnKure Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC bought a new stake in shares of OnKure Therapeutics in the 4th quarter valued at approximately $2,941,000. Shay Capital LLC increased its position in shares of OnKure Therapeutics by 17.4% during the 3rd quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock valued at $2,524,000 after purchasing an additional 135,888 shares during the last quarter. Prosight Management LP raised its holdings in OnKure Therapeutics by 204.9% during the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after buying an additional 548,950 shares during the period. Rosalind Advisors Inc. bought a new stake in OnKure Therapeutics in the fourth quarter worth $2,118,000. Finally, Renaissance Technologies LLC lifted its position in OnKure Therapeutics by 40.7% in the fourth quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock worth $717,000 after buying an additional 71,600 shares during the last quarter. 90.98% of the stock is owned by institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.